美股异动|艾伯维股价创新高连涨三日专利协议助力稳定市场优势

Group 1 - AbbVie demonstrated strong market performance with a stock price increase of 4.05% on September 11, marking a cumulative rise of 4.97% over three days, reaching an all-time high during intraday trading, reflecting market confidence in the pharmaceutical giant [1] - A significant event attracting market attention is AbbVie's patent settlement agreement with a generic drug manufacturer, ensuring that its core drug, Upadacitinib (RINVOQ), will not face generic competition until April 2037, providing a stable market advantage and a solid foundation for R&D and business expansion [1] - RINVOQ has broad applications in treating various autoimmune diseases and is set to receive EU and FDA approval for a new indication for giant cell arteritis by April 2025, further enhancing AbbVie's leadership position in the immunology field [1] Group 2 - AbbVie's strategy extends beyond a single domain, having entered the medical aesthetics and ophthalmology markets through the acquisition of Allergan, and the blood cancer sector through the purchase of Pharmacyclics, while collaborating with several biotech companies to accelerate the development and market entry of high-potential drugs [2] - The company's development path illustrates essential conditions for a successful enterprise, emphasizing the importance of not solely relying on short-term trends or blockbuster products, but rather maintaining the ability to continuously invest stable cash flow into innovation and broaden the business moat [2]